2023
Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022
Klaassen F, Chitwood M, Cohen T, Pitzer V, Russi M, Swartwood N, Salomon J, Menzies N. Changes in Population Immunity Against Infection and Severe Disease From Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variants in the United States Between December 2021 and November 2022. Clinical Infectious Diseases 2023, 77: 355-361. PMID: 37074868, PMCID: PMC10425195, DOI: 10.1093/cid/ciad210.Peer-Reviewed Original ResearchConceptsSevere diseasePopulation immunityOmicron infectionOmicron variantUS populationSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2SARS-CoV-2 infectionRespiratory syndrome coronavirus 2SARS-CoV-2 Omicron variantRestoration of immunitySyndrome coronavirus 2Bayesian evidence synthesis modelInfection-acquired immunityEvidence synthesis modelSARS-CoV-2Prior immunological exposureCoronavirus 2Additional infectionsImmunological exposureInfectionDiseaseImmunityVaccinationUnited StatesEstimated rates of progression to tuberculosis disease for persons infected with Mycobacterium tuberculosis in the United States
Ekramnia M, Li Y, Haddad M, Marks S, Kammerer J, Swartwood N, Cohen T, Miller J, Horsburgh C, Salomon J, Menzies N. Estimated rates of progression to tuberculosis disease for persons infected with Mycobacterium tuberculosis in the United States. Epidemiology 2023, 35: 164-173. PMID: 38290139, PMCID: PMC10832387, DOI: 10.1097/ede.0000000000001707.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyUS-born statusNational TB Surveillance SystemReactivation TBNutrition Examination SurveyInterferon-gammaIGRA sensitivityTB surveillance systemProgression to tuberculosis diseaseNationally representative dataEnd-stage renal diseaseReactivation rateAmerican Community SurveyExamination SurveyPerson yearsRace-ethnicityUS populationTB ratesTB incidenceCommunity SurveyRepresentative dataSurveillance systemRelease assay
2022
Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: Results of a Bayesian evidence synthesis model
Chitwood MH, Russi M, Gunasekera K, Havumaki J, Klaassen F, Pitzer VE, Salomon JA, Swartwood NA, Warren JL, Weinberger DM, Cohen T, Menzies NA. Reconstructing the course of the COVID-19 epidemic over 2020 for US states and counties: Results of a Bayesian evidence synthesis model. PLOS Computational Biology 2022, 18: e1010465. PMID: 36040963, PMCID: PMC9467347, DOI: 10.1371/journal.pcbi.1010465.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionCOVID-19 casesIncident SARS-CoV-2 infectionCOVID-19 disease burdenSymptomatic COVID-19 casesLocal epidemiological trendsSARS-CoV-2 transmissionBayesian evidence synthesis modelCOVID-19 outcomesEvidence synthesis modelMagnitude of infectionCOVID-19 deathsCumulative incidenceDisease burdenExcess mortalityCase ascertainmentEpidemiological trendsSeroprevalence estimatesUnderlying incidenceUS populationDisease trendsViral transmission dynamicsInfectionEpidemiological driversCOVID-19 epidemicPopulation Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021
Klaassen F, Chitwood MH, Cohen T, Pitzer VE, Russi M, Swartwood NA, Salomon JA, Menzies NA. Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. Clinical Infectious Diseases 2022, 76: e350-e359. PMID: 35717642, PMCID: PMC9214178, DOI: 10.1093/cid/ciac438.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionSARS-CoV-2Immunological exposureOmicron variantSevere diseaseAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionFuture SARS-CoV-2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantsUS populationSyndrome coronavirus 2 infectionCoronavirus disease 2019 (COVID-19) vaccinationCoronavirus 2 infectionPopulation-level immunityPrior immunological exposurePopulation immunityImmune escapeVaccination dataInfectionInfection statusVaccinationUS statesEffective protectionDiseaseImmunity
2020
Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020
Weinberger DM, Chen J, Cohen T, Crawford FW, Mostashari F, Olson D, Pitzer VE, Reich NG, Russi M, Simonsen L, Watkins A, Viboud C. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. JAMA Internal Medicine 2020, 180: 1336-1344. PMID: 32609310, PMCID: PMC7330834, DOI: 10.1001/jamainternmed.2020.3391.Peer-Reviewed Original ResearchConceptsCOVID-19Excess deathsOfficial COVID-19 deathsCoronavirus disease 2019Entire US populationPublic health impactCOVID-19 diagnostic testsCOVID-19 burdenCOVID-19 deathsCause deathReported deathsMortality burdenObservational studyDisease 2019Influenza activityMAIN OUTCOMEDeath AssociatedWeekly deathsTotal deathsUS deathsMore deathsDeath recordsUS populationHealth StatisticsTest availabilityTime Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States
Menzies NA, Swartwood N, Testa C, Malyuta Y, Hill AN, Marks SM, Cohen T, Salomon JA. Time Since Infection and Risks of Future Disease for Individuals with Mycobacterium tuberculosis Infection in the United States. Epidemiology 2020, 32: 70-78. PMID: 33009253, PMCID: PMC7707158, DOI: 10.1097/ede.0000000000001271.Peer-Reviewed Original ResearchConceptsLatent TB infectionMycobacterium tuberculosis infectionTB infectionTuberculosis infectionTB natural historyRisk of tuberculosisMost TB casesRate of progressionYounger age groupsLower future riskTransmission dynamic modelTB casesTB riskPrevalent infectionProgression riskLifetime riskRisk factorsIncidence trendsClinical diseaseCumulative riskGeneral populationAverage ageNew infectionsUS populationAge groups
2018
Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model
Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, Marks SM, Salomon JA. Prospects for Tuberculosis Elimination in the United States: Results of a Transmission Dynamic Model. American Journal Of Epidemiology 2018, 187: 2011-2020. PMID: 29762657, PMCID: PMC6119121, DOI: 10.1093/aje/kwy094.Peer-Reviewed Original ResearchConceptsTB preventionTB eliminationLatent TB infection (LTBI) screeningTB case detectionHigh-risk populationImportant health benefitsTransmission dynamic modelIncident TBActive TBTuberculosis eliminationInfection testingTB controlTB incidenceEpidemiologic evidenceTB transmissionInfection screeningCase detectionTuberculosis trendsUS populationRisk determinantsHealth benefitsTreatment qualityUnited StatesTreatment activitiesTreatment